Search Results - mark+greene

8 Results

Sort By:

Tumor Necrosis Factor (TNF) is a potent pro-inflammatory cytokine whose dysregulation has been found to cause rheumatoid arthritis, stroke and a broad range of inflammatory disease. Inhibition of TNF receptors has become an effective means to ameliorate inflammatory disease, however, pan TNF-R antagonists increase risk of infection and malignancy. Using...

Published: 6/21/2024 | Inventor(s): Mark Greene

Keywords(s):

Category(s): Technology Classifications > Therapeutics

Treating Prostate Cancer with Novel Sugar-Antigen-Targeting CAR-T Cells

Problem: While the 5-year relative survival rate for patients with local or regional prostate cancer is nearly 100%, the 5-year relative survival rate drops to 32% for patients with metastatic or advanced disease. These patients may initially respond to available therapies, but most patients will develop therapy resistance and succumb to disease. Solution: A...

Published: 6/20/2024 | Inventor(s): Mark Greene, Michael Milone

Keywords(s): Cell Therapy, Oncology

Category(s): Technology Classifications > Therapeutics

Antibody-like therapeutic platform with effector function

Technology Overview: While antibody therapeutics have proven to be successful in recent years, they are not without drawbacks. The large size of antibodies can prevent their effective use against certain cancers, as well as prevent them from crossing the blood-brain barrier. Additionally, many antibodies require post-translational modifications and...

Published: 2/12/2024 | Inventor(s): Mark Greene

Keywords(s): Antibody

Category(s): Technology Classifications > Therapeutics

Diagnosis and treatment of prostate cancer using a prostate cancer antibody

Monoclonal antibody and immunotherapy use in prostate cancer Technology Overview: Both androgen dependent and independent prostatic carcinomas have a high potential to metastasize. Unfortunately, the overall 5-year survival rate for metastatic prostate cancer is only 34%. Dr. Greene and his collaborators at the University of Pennsylvania have developed...

Published: 2/12/2024 | Inventor(s): Mark Greene

Keywords(s): Oncology

Category(s): Technology Classifications > Diagnostics, Technology Classifications > Therapeutics

Her2/Neu inhibitors for cancer therapy and molecular imaging

Cancer affects approximately 10 million people globally, with breast and lung cancer accounting for 25% of cancer incidences. Assuming over expression of Her2 is responsible for 25% of the breast cancer and lung cancer, and then the estimated market is about one million. The estimated price of Lapatinib, a small molecule tyrosine kinase inhibitor,...

Published: 2/12/2024 | Inventor(s): Mark Greene

Keywords(s): Oncology

Category(s): Technology Classifications > Therapeutics, Technology Classifications > Imaging

Therapy for heparin-induced thrombocytopenia (HIT) targeting the epitope structure of the disease –inducing antibody

Technology Overview: Roughly 12 million patients are exposed to heparin annually and up to 1% of these patients will develop heparin-induced thrombocytopenia/thrombosis (HIT), a life-threatening complication where patients make antibodies that bind to the heparin/PF4 complex, resulting in thrombosis and thrombocytopenia. The Greene lab has identified...

Published: 6/20/2024 | Inventor(s): Mark Greene

Keywords(s): Antibody

Category(s): Technology Classifications > Diagnostics, Technology Classifications > Research Tools & Reagents, Technology Classifications > Therapeutics

TIP60 inhibitors – therapy for Irritable Bowel Disease (IBD); ulcerative colitis and Crohn’s diseases

Inhibitors of TIP60, maintaining regulatory T cells (Tregs) and ameliorating autoimmune diseases. Problem: Inflammatory bowel disease (IBD) involves chronic inflammation of all or part of digestive tract. IBD includes ulcerative colitis and Crohn’s disease both very prevalent and known to cause severe complications and discomfort. Inhibitors...

Published: 2/12/2024 | Inventor(s): Mark Greene

Keywords(s):

Category(s): Technology Classifications > Therapeutics

A method to identify modulators for regulatory T cell functions

Technology Overview: Maintenance of tolerance to self-antigens is essential for the prevention of autoimmunity. This process is known to involve specific regulatory T cells (Treg) and the expression of the forkhead family transcription factor, FOXP3. FOXP3 is a “sufficient” regulator of the development and function of peripheral Treg...

Published: 2/12/2024 | Inventor(s): Mark Greene

Keywords(s): Immunology

Category(s): Technology Classifications > Research Tools & Reagents